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ABSTRACT 
Objective: Development of effective drug delivery in the treatment of psoriasis is the major challenge for its successful management. To develop 
and assess the potential of Nanostructured Lipid Carriers (NLCs) enriched with the powdered leaves extracts of Azadirachta indica (AE), Lawsonia 
inermis (LE) and fruit extract of Mallotus philippensis (ME) in the management of psoriasis.  
Methods: Drug loaded NLCs were prepared via hot homogenization technique by adopting 23
Results: The optimized batch of NLCs was found within the nanosized range with a relatively low polydispersity index and zeta potential of-20mV. 
The %EE for an optimized batch of NLCs was found to be 98.97±0.83%, 96.99±0.56% and 99.25±0.55% and the %DL of 21.84±0.15%, 8.55±045%, 
and 87.91±0.38% respectively for AE, LE and ME.  
 factorial design with factors X1 as the concentration 
of lipids, X2 concentration of surfactants and X3 being the number of homogenization cycle. The responses Y1 and Y2 were particle size and zeta 
potential. The optimized batch was obtained from Surface response plot and was evaluated for zeta potential, % entrapment efficiency, % drug 
loading, Scanning Electron Microscopy(SEM), % in vitro diffusion of drugs from the NLCs, anti-lipid peroxidation and nitric oxide scavenging 
activities, cytotoxicity on HaCat cell lines, Mouse Tail and Rat ultraviolet ray B photodermatitis models for Psoriasis. 
The SEM images showed the spherical vesicular structures of drugs loaded NLCs. The in-vitro diffusion of drugs from the NLCs followed initial burst 
release thereafter sustained release for 24 h. The AE, LE and ME loaded NLCs proved to possess anti-lipid peroxidation and nitric oxide scavenging 
activities, cytotoxicity on HaCat cell lines, DNA fragmentation on HaCat cell lines which are biomarkers in the pathogenesis of psoriasis. The results 
of Mouse Tail and Rat ultraviolet ray B photodermatitis models for Psoriasis supported the anti-psoriatic potential of AE, LE and ME loaded NLCs. 
Conclusion: AE, LE and ME loaded NLCs can be used for prolonged topical delivery to the psoriatic skin for an effective treatment. 
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INTRODUCTION 
Psoriasis is a common skin disease characterized by hyper-
proliferation of epidermal cells of skin [1]. Although extensive work 
has been reported, the development of effective drug delivery is the 
major challenge for the successful management of this disease [2-
27]. The barrier effect of skin offers several challenges for the topical 
bioavailability from conventional formulations. The literature 
review indicates the potential role of Nanostructured Lipid Carriers 
(NLCs) in the topical treatment of psoriasis [20-27]. Attempts to use 
topical allopathic treatments like corticosteroids, calcipotriene, 
retinoids, coal tar, anthralin, clobetasol propionate, methotrexate, 
cyclosporines have failed due to their toxicities and inappropriate 
formulation design of the conventional dosage forms [28-30]. The 
literature survey reveals that Azadirachta indica, Lawsonia 
inermis, and Mallotus philippensis exhibit anti-inflammatory 
activities in addition to their multitude of medicinal properties 
and have been used in combination in traditional medicine in the 
treatment of Psoriasis [31-35]. Different nanoparticulate drug 
delivery systems of Azadirachta indica have been reported in the 
literature such as Nanoemulsion, Nanocapsules, Solid lipid 
nanoparticles, and the Niosomes and Silver Nanoparticles of 
Lawsonia inermis leaves extract but no work has been done on 
nanoparticulate drug delivery system of Mallotus philippensis [36-
40]. Also, the literature survey revealed the absence of 
Azadirachta indica, Lawsonia inermis, and Mallotus philippensis 
extracts loaded NLCs for the treatment of psoriasis. Therefore, the 
present research was undertaken to investigate and assess the 
potential of Nanostructured Lipid Carriers (NLCs) enriched with 
the powdered leaves extracts of Azadirachta indica (AE), Lawsonia 
inermis (LE) and fruit extract of Mallotus philippensis (ME) 
respectively. In this study the authors have investigated the long-
term safety and efficacy of a three-compound formulation AE, LE 
and ME extract for the treatment of psoriasis.  
MATERIALS AND METHODS 
Materials 
The Dried herbs of Azadirachta indica Leaves, Lawsonia inermis Leaves 
and Mallotus philippensis powder were purchased from local vendors 
and authenticated (Ref No.: Bot/10/2017) from the Department of 
Botany, Savitribai Phule University of Pune, India. The solid lipids were 
obtained as gift samples from Gattefosse, France. Rest all chemicals were 
of AR grade and were purchased from Sigma Aldrich.  
Preparation of Azadirachta indica extract (AE), Lawsonia 
inermis extract (LE) and Mallotus philippensis extract (ME) 
loaded NLCs 
The extracts were prepared from the leaves of Azadirachta indica 
and Lawsonia inermis using the Soxhlet apparatus and that of 
Mallotus philippensis fruits by maceration process and Drug loaded 
NLCs were produced by hot high-pressure homogenization method 
[41]. The factorial batches of AE, LE and ME loaded NLCs were 
prepared by applying 23Factorial Design [42] with factors, X1 
(Stearic acid: Seasame oil, Mustard oil concentration), X2 (Tween80: 
Span 20 concentration) and X3 (number of homogenization cycle) as 
three independent variables at two levels–1 and+1. The two 
dependent responses were Y1 (Particle size) and Y2 (Zeta Potential). 
Accordingly, a total of eight formulations were designed and the 
compositions of different formulations have been depicted in table 
1. The pre-emulsion was prepared by thoroughly dissolving the ME 
in the lipid phase containing stearic acid, sesame oil, mustard oil and 
span 20 at 65 °C, the oil phase was immediately dispersed into the 
hot aqueous phase consisting of Tween 80, AE and LE at 65 °C under 
constant stirring at 8000 rpm for 20 min using Ultra Turrax IKA T25, 
(Remi Motors Ltd, RM-12C Mumbai). For 2 gm of lipid mixture, 200 
mg of AE, LE and ME mixture was taken in the ratio of 2.5:1:10. The 
pre-emulsion was further processed by high-pressure homogenizer 
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(Nitro Soavi, Italy) using 5 and 3 homogenization cycles (For 
factorial batches) at the temperature of 65 °C with 500bars pressure 
and cooled to room temperature so as to crystallize the lipid and 
finally formed the active-loaded NLCs. 
  




Coded form Actual form AE, LE and 
ME (mg) 
Sr. No. NLC X1 X2 X3 Conc. Of SA: SO and MO (g) Conc. Of Tw80: Sp20 (g) No. of Homogeni-zation cycles 
1. F1 + - + 1.6 0.4 5 200 
2. F2 + - - 1.6 0.4 3 200 
3. F3 + + + 1.6 0.8 5 200 
4. F4 + + - 1.6 0.8 3 200 
5. F5 - - + 1.2 0.4 5 200 
6. F6 - - - 1.2 0.4 3 200 
7. F7 - + + 1.2 0.8 5 200 
8. F8 - + - 1.2 0.8 3 200 
 
Physicochemical characterization of AE, LE and ME loaded NLC 
Mean particle size, size distribution and charge on drug-loaded 
droplet surface of factorial batches of NLCs were determined by 
dynamic light scattering using Malvern Zetasizer at room 
temperature. Before measurement, batches were diluted with 
filtered double distilled water (1:1000) until the appropriate 
concentration of particles was achieved to avoid multi-scattering. 
The diluted samples were filled in the disposable transparent sizing 
cuvettes for measurement [43, 44].  
Determination of drug entrapment efficiency (% EE)  
AE, LE and ME entrapped within the NLCs were determined by 
centrifugation method. A volume of 10 ml of NLC dispersion was 
withdrawn and transferred to the Eppendorf tube. The unentrapped 
drug was separated from the NLCs by subjecting the dispersion to 
centrifugation in a cooling centrifuge (Remi Instrument Ltd, 
Mumbai) at 15000 rpm at a temperature of 4 °C for 60 min, 
whereupon the particles of NLCs and the supernatant containing the 
free drug were obtained. The supernatant was analyzed in triplicate 
for the drug content after suitable dilution with methanol by 
measuring absorbance at 214, 276 and 297 nm for AE, LE and ME 
using UV-VIS spectrophotometer [45].  
The % entrapment efficiency was expressed as the percentage of 
total drug entrapped using the following formula:  
 
Determination of % drug loading (% DL)  
For the determination of drug loading capacity, accurately weighed 
5 mg of NLCs were dissolved in 5 ml of methanol and the solution 
was filtered through Whatman filter paper grade 41 to get recovered 
NLCs and the drug concentrations were determined using UV visible 
spectrophotometer at 214, 276 and 297 nm respectively for AE, LE 
and ME samples [46]. The percentage of drug loading capacity was 
determined using the following formula:  
% Drug Loading =  
Mass of Drugs in NLCs
Mass of NLCs recovered
× 100 
In vitro % drug diffusion  
In vitro diffusion studies were performed using DBK diffusion cell 
apparatus and dialysis membrane-70 (PALL Corporation) with 
average diameter 17.5 mm and molecular weight cut-off between 
12,000–14,000. Phosphate buffer pH-6.8: Methanol (7:3) was used 
as a diffusion medium. The dialysis membrane soaked for 12 h prior 
to the study with 50 mg of lyophilized NLCs was mounted on the 
Franz diffusion cells filled with 20 ml of diffusion media with 
constant stirring at 200rpm at 37 °C±0.5 °C. Accurately measured 1 
ml of the sample was withdrawn at time intervals of one hour for 24 
h maintaining the sink condition, followed by dilution with the 
Phosphate Buffer pH-6.8: Methanol (7:3) in the ratio 1:10. The 
samples were analyzed at a wavelength 214 nm, 276 and 297 nm for 
AE, LE and ME respectively using UV spectrophotometer (V-630, 
Jasco International, Tokyo, Japan). The cumulative % drug diffused 
for each drug in the NLC was determined graphically [47]. 
Scanning electron microscopy (SEM) of AE, LE and ME loaded 
NLC  
SEM analysis of the AE, LE and ME loaded NLCs was carried by drop-
casting method on a silicon wafer. A drop of NLC dispersion was 
used as a sample for SEM analysis. The sample was analyzed under 
the Scanning Electron Microscope (SEM, Nova Nano SEM) at an 
accelerating voltage of 20 kV [44, 47].  
Lipid peroxidation assay 
Lipid peroxidation was determined based on the amount of 
Thiobarbituric acid reactive substances. The HepG2 cells were 
seeded in 24-well culture plates at an initial density of 2*105 
cells/ml and grown to approximately 80% confluence. Oxidative 
stress was induced by treating the cells with freshly prepared H2O2. 
The cells were pretreated with samples (NLCs) at indicated 
concentrations for 24 h. Fetal Bovine Serum-free Dulbecco's 
Modified Eagle's medium containing H2O2
The percentage inhibition of lipid peroxidation was calculated using 
the following formula:  
% inhibition =
Absorbance (control) − Absorbance (test sample)
Absorbance (control)
× 100 
 (882nM) was added to 
each well and the cell plate was incubated for 24 h. The HepG2cells 
were lysed by using the freeze-thaw method. After analysis, 0.2 ml of 
the cell suspension was added to the Thiobarituric acid reagent. This 
mixture was incubated at 90 °C for 1 h and then cooled. Four 
milliliters of a mixture of n-butanol and pyridine (15:1, v/v) was 
added and was centrifuged for15 min and the absorbance was 
measured at 532 nm [48, 49]. 
Nitric oxide scavenging assay 
Accurately 200 µl of 10 mmol sodium nitroprusside and 200 µl of 
the test solution and reference standard of various concentrations 
were incubated at room temperature for 150 min. About 500 µl 
Griess reagent was added and was subjected to incubation for 10 
min at room temperature. The absorbance was measured at 546 nm. 
Test substances were replaced by Phosphate buffer solution pH 7.0 
for control [50]. 
The percentage inhibition of Nitric Oxide was calculated as follows:  
% inhibition =
Absorbance (control) − Absorbance (test sample)
Absorbance (control)
× 100 
Cytotoxicity studies on HaCat cell lines 
HaCaT cell line was procured from ATCC, stock cells were cultured 
in Dulbecco's Modified Eagle's medium supplemented with 10% 
inactivated Fetal Bovine Serum, Penicillin (100 IU/ml), 
Streptomycin (100 µg/ml) in a humidified atmosphere of 5% Carbon 
dioxide at 37 °C. Serial two-fold dilutions (0-100µM) were prepared 
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for carrying out cytotoxic studies. The monolayer cell culture was 
trypsinized and the cell count was adjusted to 1.0 x 105 cells/ml 
using respective media containing 10% Fetal Bovine Serum. To each 
well of the 96 well microtiter plate, 100 µl of the diluted cell 
suspension (50,000 cells/well) was added. After 24 h, when a partial 
monolayer was formed, the supernatant was discarded, washed the 
monolayer once with medium and 100 µl of different test 
concentrations of NLCs was added on to the partial monolayer in 
microtiter plates followed by incubation at 37 °C for 24 h in 5% 
Carbon dioxide atmosphere. After incubation, the test solutions in 
the wells were discarded and 100 µl of 3-[4, 5-dimethylthiazol-2-yl]-
2, 5-diphenyl tetrazolium bromide (5 mg/10 ml of MTT in USP 
Phosphate buffer pH 7.0) was added to each well. The plates were 
incubated for 4 h at 37 °C in a 5% Carbon dioxide atmosphere. The 
supernatant was removed and 100 µl of Dimethyl sulfoxide was 
added and the plates were gently shaken to solubilize the formed 
formazan. The absorbance was measured using a microplate reader 
at a wavelength of 590 nm. The percentage growth inhibition was 
calculated using the following formula and concentration of test 
drug needed to inhibit cell growth by 50% (IC50
HaCat cells were seeded at a concentration of 1x10
) values were 
generated from the dose-response curves for each cell line [51, 52]. 




DNA fragmentation studies on HaCat cell lines 
6 per 35 mm dish 
incubated at 37 °C/5 % Carbon dioxide for 24 h. The confluent cells 
grown after 24 h of incubation were treated with sample 
conc.160μg/ml, 320μg/ml and control. After treatment, cells were 
trypsinized, and both adherent and floating cells were collected by 
centrifugation at 2000 rpm for 5 min. The cell pellet was suspended 
in 0.5 ml lysis buffer pH 7.8 containing a mixture of Tris-
Hydrochloric acid 10 mmol, pH 8; Ethylene diamine tetraacetic acid 
20 mmol, pH 8.0; TritonX-100 0.2% or Sodium-N-lauroyl 
sarcosinate, 4M Sodium chloride, vortex vigorously and incubated at 
50 °C for 5 min. To the lysate, 0.5 ml of phenol-chloroform iso-amyl 
alcohol was added and mixed for 2-3 min and centrifuged at 10000 
rpm for 15 min at 4 °C. The upper aqueous layer was taken in a new 
tube, to which double the volume of cold 100% ethanol was added 
and 3M sodium acetate was added to make a final concentration of 
sodium acetate 0.3 M. The sample was incubated for 5-10 min at 
room temperature and centrifuged at 10000 rpm 
Mouse-tail model for psoriasis 
for 15 min. After 
removing the supernatant, the DNA pellets were washed with 70% 
ethanol and centrifuged at 5000 rpm for 10 min followed by removal 
of supernatant and air drying of DNA pellets that were dissolved in 
tris buffer and separated by 2% agarose gel electrophoresis at 100 
volts for 50 min [53, 54]. 
All procedures of the study were in accordance with the guidelines 
set by the CPCSEA and an approved IAEC protocol number (IAEC-
17-019). 15 male Swiss albino Mice obtained from the National 
Institute of Bioscience, Pune were allowed to acclimatize for 5 d and 
randomly allotted to three groups, 6 mice per standard Group I, 
Clobetasol propionate 0.05% cream and NLCs Group II and 3 mice 
for placebo control Group III. The samples were applied to tails 
treated locally at the rate of 2-5 mg per animal to the proximal part 
of the tail uniformly. For the contact time of 2 h, a plastic cylinder 
was slipped over the tail and fixed with adhesive tape. At the end of 
contact time, the cylinders were removed and the tails were wiped 
with cotton. Mice were treated once daily, for 2 w. Two hours after 
the last treatment the animals were sacrificed and the tails were 
fixed in 10% buffered formalin and processed for histopathology. 
Longitudinal sections of about 5μm thickness were prepared and 
stained with hematoxylin-eosin and permanent slides were 
prepared for evaluation. Sections were examined under a light 
microscope to observe alterations in epidermal thickness, 
elongation of ridges and orthokeratosis. The animals were also 




Fig. 1: Particle size analysis of factorial batches of AE, LE and ME loaded NLCs, Foot Note: (n=1) AE= Azadirachta indica extract, LE= 
Lawsonia inermis extract, ME= Mallotus phillipensis extract, NLCs= nanolipid carriers 
 
Rat ultraviolet ray B photodermatitis model for psoriasis 
Healthy male Sprague Dawley rats obtained from National Institute 
of Bioscience, Pune weighing 150-200 gm were kept in 12hour light: 
12 hr dark cycle at 20.4 to 23.8 °C temperature and 36 to 61 % RH 
with the provision of food (ad libitum) and water (Reverse osmosis 
water treated with Ultraviolet light) were carefully maintained. All 
procedures of the study were in accordance with guidelines set by 
the CPCSEA and an approved IAEC protocol number (IAEC-17-009). 
The study design comprised of three groups, Group I (2-5 mg/kg of 
Clobetasol propionate 0.05% cream as standard) 6 animals, Group II 
(2-5 mg/kg of AE, LE and ME loaded NLCs) 6 animals and Group III 
(2-5 mg/kg of Placebo cream) 3 animals respectively. The hair on 
the dorsal skin was clipped and carefully shaved. An area (1.5 x 2.5 
cm) on one side of the flank was irradiated for 15 min (1.5 J/cm2) at 
a vertical distance of 20 cm with UV-B LAMPS. Biphasic erythema 
was observed. After 72 h irradiation the test anti-psoriatic cream, 
standard cream, and placebo cream were applied at the 2-5 mg/rat 
topically on the irradiated site daily once. The irradiated rats were 
sacrificed on day 11 after UV-B irradiation by CO2 anesthesia. Skin 
biopsies were taken immediately, and fixed in 10% formalin and 
embedded in paraffin. Tissue sections (4 μm thick) were stained 
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with hematoxylin and eosin. Sections were examined under a light 
microscope to observe alterations in epidermal thickness, 
elongation of ridges and orthokeratosis. Parameters evaluated 
included mortality and clinical signs observations and body weight. 
All the data were analyzed using one way ANOVA followed by 
Dunnett’s Multiple Comparison test [56, 57].  
RESULTS AND DISCUSSION 
Physicochemical characterization of factorial batches of AE, LE 
and ME loaded NLC 
The dynamic light scattering method was employed for the 
determination of particle size and the charge on the surface of NLC 
droplets by using the Malvern Zetasizer (Hydro MU 2000, UK). The 
PDI values of the factorial batches of NLCs were obtained in a range 
of 0.453–1.01 with PDI of an optimized batch as 1, implying the 
polydispersity of NLCs. Zeta potential of-20 mV indicated good 
stability of colloidal dispersion. Average diameters, PDI and zeta 
potential of factorial batches of AE, LE and ME enriched NLCs have 
been shown in fig. 1. 
Determination of %EE and %DL of factorial batches of AE, LE 
and ME loaded NLC 
AE, LE and ME entrapped within the NLCs were determined by 
centrifugation method and were found to be in the range 98.65±0.06 
to 99.07±0.09%, 94.58±0.31 to 95.91±0.09% and 98.79±0.24 to 
99.08±0.58% respectively for AE, LE and ME as depicted in fig. 2 and 
the % drug loading of AE, LE and ME in NLC formulations ranged 
between 11.39±0.46 to 45.23±0.54%, 14.49±0.67-to45.23±0.37 and 
40.85±0.89 to 86.24±0.74% respectively as depicted in fig. 3. 
 
 
Fig. 2: % Entrapment efficiency of factorial batches of AE, LE and ME loaded NLCs, Foot Note: (n=3) all data representing an average of 3 
trials, given as mean±SD, AE= Azadirachta indica extract, LE= Lawsonia inermis extract, ME= Mallotus phillipensis extract, NLCs= 
Nanolipid Carriers, %EE= percentage entrapment efficiency 
 
 
Fig. 3: % Drug loading of factorial batches of AE, LE and ME loaded NLCs, Foot Note: (n=3) all data representing an average of 3 trials, 
given as mean±SD, AE= Azadirachta indica extract, LE= Lawsonia inermis extract, ME= Mallotus phillipensis extract, NLCs= Nanolipid 
Carriers, %DL= percentage drug loading 
 
In vitro % drug diffusion studies of factorial batches of AE, LE 
and ME loaded NLCs 
In vitro % drug diffusion of factorial batches of AE, LE and ME loaded 
NLC was determined using franz diffusion cell apparatus that was 
found to range between 80.46±0.31 to 91.11±0.52%, 80.46±0.51 to 
94.57±0.14% and 86.85±0.22 to 95.28±0.27% respectively at 24 h 
(fig. 4, 5 and 6). During the preparation of NLCs, cooling from high 
temperature to room temperature favors the enrichment of the drug 
in the outer layers of the particles resulting in superficial 
entrapment causing initial burst release. 
Optimization of factorial batches of AE, LE and ME loaded NLC 
A 23 randomized full factorial design was utilized in the present 
study. The different independent variables included Stearic Acid: 
Seasame oil and Mustard oil concentration (X1), Tween20: Tween80 
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concentration (X2) and Number of HPH cycles (X3). The batches 
were evaluated and the effect of an individual variable was studied 
according to the response surface methodology. The dependent 
response was Particle Size (Y). The three-dimensional (3D) response 
surface graphs depict the effect of the independent variables on the 
response (fig. 7). 
 
 








Fig. 6: Cumulative % drug diffusion of ME, Foot Note: (n=3) all data representing an average of 3 trials, given as mean±SD, ME= Mallotus 
phillipensis extract  
Bhise et al. 




Fig. 7: Response surface plot (3D Surface Plot) showing the effect of formulation variables on particle size (Y1) of AE, LE and ME loaded 
NLCs 
 
Physicochemical characterization of optimized batch of AE, LE 
and ME loaded NLC 
The mean particle diameter/Z-average of the optimized batch of AE, 
LE and ME NLCs was found to be 185 nm Zeta potential of optimized 
formulation of AE, LE and ME loaded NLC was found to be-20 mV 
that indicates good stability of colloidal dispersion. 
%EE and % DL of an optimized batch of NLCs 
The %EE for the optimized batch of NLCs was found to be 98.97±0.83%, 
96.99±0.56% and 99.25±0.55% and the %DL of 21.84±0.15%, 
8.55±045%, and 87.91±0.38% respectively for AE, LE and ME with n=3.  
Scanning electron microscopy (SEM) optimized batch 
The SEM photomicrograph as indicated in fig. 8 reveals the spherical 
and smooth surface of the NLCs. 
In vitro % drug diffusion of an optimized batch of AE, LE and ME 
loaded NLC 
As depicted in fig. 9 it was observed that % drug diffusion of AE, LE 
and ME was 90.87±4.71%, 92.64±1.56%, and 93.93±1.69 % 
respectively at 24th
Lipid peroxidation assay 
 h. 
Lipid peroxidation indicates the generation of malondialdehyde, 
increased levels of which play a significant role in the pathogenesis 
of Psoriasis [58]. The reduction in the levels of Malondialdehyde 
after application of AE, LE and ME loaded NLCs supported a 
reduction in inflammation and pathogenesis of psoriasis. As 
represented in fig. 10 the IC50 
  
value of AE, LE and ME loaded NLCs 
for inhibition of lipid peroxidation was found to be 571.20 µg/ml 
confirming a dose-dependent increase in anti-lipid peroxidation. 
 
Fig. 8: Scanning electron microscopy of an optimized batch of AE, LE and ME loaded NLCs 
Bhise et al. 




Fig. 9: In vitro cumulative % drug diffusion for an optimized batch of AE, LE and ME loaded NLCs, Foot Note: (n=3) all data representing an 
average of 3 trials, given as mean±SD, AE= Azadirachta indica extract, LE= Lawsonia inermis extract, ME= Mallotus phillipensis extract, 
NLCs= nano lipid carriers 
 
 
Fig. 10: Lipid peroxidation inhibition for optimized batch of AE, LE and ME loaded NLCs Foot Note: (n=1) AE= Azadirachta indica extract, 
LE= Lawsonia inermis extract, ME= Mallotus phillipensis extract, NLCs= Nanolipid Carriers, MDA= Malondialdehyde 
 
 
Fig. 11: % Nitric oxide inhibition for optimized batch of AE, LE and ME loaded NLCs, Foot Note: (n=1), AE= Azadirachta indica extract, LE= 
Lawsonia inermis extract, ME= Mallotus phillipensis extract, NLCs= nanolipid carriers 
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Nitric oxide scavenging assay 
The nitric oxide scavenging activity was determined to assess 
peroxynitrite formation as it is an important factor in tissue-
damaging mechanisms such as chronic inflammation [59]. The 
results presented in fig. 11 indicate the IC50 value of 899.79µg/ml 




HaCat cells treated with sample 160μg/ml, 320μg/ml have shown 
dose-dependent increased DNA fragmentation as compared with 
control. Overall, these results suggest that the sample induces DNA 
fragmentation; a marker of apoptotic activity in AE, LE and ME 
loaded NLCs.  
values for cytotoxicity test of AE, LE and ME loaded NLCs was 
derived from nonlinear regression analysis (curve fit) based on 
sigmoid dose-response curve (variable) and computed using Graph 
Pad Prism 6 (Graph pad, SanDiego, CA, USA) was found to be 164.2 
µg/ml. 
DNA fragmentation 
Mousetail model for psoriasis 
The objective of this Antipsoriatic activity study was to assess the 
orthokeratotic cell differentiation in the epidermal scales after the 
application of the formulation. No mortality or abnormal clinical 
signs or adverse effects of body weight gain were observed in any of 
the mice from the entire three groups until the scheduled necropsy.  
Histopathology 
Histopathological observations of the longitudinal sections of mouse 
tail skin from placebo Group III revealed the normal thickness of the 
epidermis, presence of ridges and presence of parakeratotic layer 
[fig. 12 (c)]. The mouse tail skin from standard Group I (Clobetasol 
propionate cream 0.05%) and test Group II (NLCs) groups revealed 
marked reduction in the thickness of the epidermal layer, a decrease 
in ridges and presence of granular cells in orthokeratotic layer [fig. 
12 (a) and (b)] respectively. 
 
 
Fig. 12: Histopathology of mice tail skin for, a) Standard Group I, b) Test group II, c) Placebo group III 
 
Rat ultraviolet ray B photodermatitis model for psoriasis 
All the animals survived till the scheduled necropsy, there was no 
mortality or abnormal clinical signs of adverse effects on body 
weight gained of treated animals were observed in any animal 
throughout the treatment period. Animals were sacrificed on day 11 
after induction of dermatitis and drug application. No gross 
pathological findings were observed in any of the control and 
treated animals. 
Histopathology 
Histopathological observations of the longitudinal sections of rat 
skin from placebo Group III revealed the increased thickness of 
epidermis with inflammatory changes [fig. 13 (c)]. The rat skin from 
standard Group I (Clobetasol propionate cream 0.05%) and test 
Group II (NLCs) groups revealed a marked reduction in the 
thickness of the epidermal layer and inflammatory changes [fig. 13 
(a) and (b) respectively]. 
  
 
Fig. 13: Histopathology of Rat Skin for, a) Standard group I, b) Test group II, c) Placebo group III 
 
FUTURE DIRECTION AND CONCLUSION 
Nanotechnology is a growing field and is convincing to many 
researchers. Properly synthesized NLCs strategies result in the 
improvement of bioactivity and bioavailability of traditional herbs 
through encapsulation, particle size reduction, surfaces 
modification and bioactive materials entrapment for topical 
treatment of psoriasis. From the results of the cumulative drug 
diffusion studied, cell line studies and advanced preclinical trials 
of mouse tail and rat skin, it can be concluded that the AE, LE and 
ME loaded NLCs can be used for prolonged topical delivery of 
drugs to the psoriatic skin.  
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